A new antiepileptic medication has been launched in the UK as adjunctive therapy for the treatment of partial-onset seizures, with or without secondary generalisation, in adults.
Eslicarbazepine acetate (Zebinix®) is available as 800mg tablets in packs of 30 at a cost of £154.20. The drug is an active metabolite of oxcarbazepine and has the same mechanism of action as carbamazepine.
Concomitant use with oxcarbazepine is not recommended due to the theoretical risk of overexposure to the active metabolites of these drugs. The only apparent advantage of this drug over oxcarbazepine is the once daily administration however this comes at a significant cost.
Action: Clinicians should be aware of this new drug. This new drug may be useful where compliance with twice daily oxcarbazepine is incomplete but changes to therapy should ideally be secondary care led.